Abstract
BackgroundAdoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved CAR-T cell products use the FMC63-based...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have